AGFA-GEVAERT NV (AGFB.BR)
BE0003755692 - Common Stock
Taking everything into account, AGFB scores 2 out of 10 in our fundamental rating. AGFB was compared to 14 industry peers in the Health Care Technology industry. The financial health of AGFB is average, but there are quite some concerns on its profitability. AGFB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year AGFB has reported negative net income.
In the past year AGFB has reported a negative cash flow from operations.
In the past 5 years AGFB reported 4 times negative net income.
In the past 5 years AGFB reported 4 times negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -20.45%, AGFB is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -65.96%, AGFB is doing worse than 76.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.45% | ||
| ROE | -65.96% | ||
| ROIC | N/A |
ROA(3y)-6.95%
ROA(5y)0.93%
ROE(3y)-23.67%
ROE(5y)-5.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of AGFB (29.54%) is worse than 84.62% of its industry peers.
AGFB's Gross Margin has been stable in the last couple of years.
AGFB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5Y-0.57%
2. Health
2.1 Basic Checks
AGFB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGFB has about the same amount of shares outstanding.
The number of shares outstanding for AGFB has been reduced compared to 5 years ago.
The debt/assets ratio for AGFB is higher compared to a year ago.
2.2 Solvency
AGFB has an Altman-Z score of 2.03. This is not the best score and indicates that AGFB is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.03, AGFB is in line with its industry, outperforming 46.15% of the companies in the same industry.
A Debt/Equity ratio of 0.16 indicates that AGFB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.16, AGFB is in line with its industry, outperforming 53.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.03 |
ROIC/WACCN/A
WACC6.94%
2.3 Liquidity
A Current Ratio of 2.12 indicates that AGFB has no problem at all paying its short term obligations.
AGFB's Current ratio of 2.12 is fine compared to the rest of the industry. AGFB outperforms 69.23% of its industry peers.
AGFB has a Quick Ratio of 1.21. This is a normal value and indicates that AGFB is financially healthy and should not expect problems in meeting its short term obligations.
AGFB has a Quick ratio of 1.21. This is in the lower half of the industry: AGFB underperforms 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.21 |
3. Growth
3.1 Past
The earnings per share for AGFB have decreased strongly by -370.60% in the last year.
Looking at the last year, AGFB shows a very negative growth in Revenue. The Revenue has decreased by -28.31% in the last year.
Measured over the past years, AGFB shows a very negative growth in Revenue. The Revenue has been decreasing by -12.10% on average per year.
EPS 1Y (TTM)-370.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q13.99%
Revenue 1Y (TTM)-28.31%
Revenue growth 3Y-12.37%
Revenue growth 5Y-12.1%
Revenue growth Q2Q-40.93%
3.2 Future
Based on estimates for the next years, AGFB will show a very strong growth in Earnings Per Share. The EPS will grow by 32.12% on average per year.
Based on estimates for the next years, AGFB will show a small growth in Revenue. The Revenue will grow by 5.28% on average per year.
EPS Next Y89.62%
EPS Next 2Y47.66%
EPS Next 3Y32.12%
EPS Next 5YN/A
Revenue Next Year2.59%
Revenue Next 2Y3.23%
Revenue Next 3Y5.28%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AGFB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGFB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as AGFB's earnings are expected to grow with 32.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.66%
EPS Next 3Y32.12%
5. Dividend
5.1 Amount
No dividends for AGFB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGFA-GEVAERT NV
EBR:AGFB (4/19/2024, 2:56:28 PM)
1.15
-0.02 (-1.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap178.04M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.45% | ||
| ROE | -65.96% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.54% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.97
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-370.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y89.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-28.31%
Revenue growth 3Y-12.37%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y